Citigroup
XENE icon

Citigroup’s Xenon Pharmaceuticals XENE Stock Holding History

Citigroup’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.56M Buy
92,124
+79,973
+658% +$4.44M ﹤0.01% 2064
2026
Q1 		$707K Buy
12,151
+4,790
+65% +$221K ﹤0.01% 3336
2025
Q4 		$330K Sell
7,361
-7,509
-50% -$315K ﹤0.01% 3772
2025
Q3 		$597K Sell
14,870
-21,420
-59% -$754K ﹤0.01% 3488
2025
Q2 		$1.14M Buy
36,290
+29,261
+416% +$954K ﹤0.01% 3099
2025
Q1 		$236K Buy
7,029
+581
+9% +$22.1K ﹤0.01% 4105
2024
Q4 		$253K Buy
6,448
+2,800
+77% +$116K ﹤0.01% 4266
2024
Q3 		$144K Sell
3,648
-190
-5% -$7.66K ﹤0.01% 4580
2024
Q2 		$150K Buy
3,838
+1,425
+59% +$57K ﹤0.01% 4024
2024
Q1 		$104K Sell
2,413
-591
-20% -$27.2K ﹤0.01% 4275
2023
Q4 		$138K Buy
3,004
+138
+5% +$4.88K ﹤0.01% 4079
2023
Q3 		$97.9K Sell
2,866
-1,288
-31% -$48.2K ﹤0.01% 3932
2023
Q2 		$160K Sell
4,154
-3,663
-47% -$146K ﹤0.01% 4005
2023
Q1 		$280K Buy
7,817
+6,008
+332% +$222K ﹤0.01% 3538
2022
Q4 		$71.3K Buy
1,809
+92
+5% +$3.35K ﹤0.01% 4160
2022
Q3 		$62K Sell
1,717
-201
-10% -$7.23K ﹤0.01% 4299
2022
Q2 		$58K Sell
1,918
-100,557
-98% -$3.04M ﹤0.01% 4475
2022
Q1 		$3.13M Buy
102,475
+100,174
+4,353% +$3M ﹤0.01% 1973
2021
Q4 		$72K Sell
2,301
-328
-12% -$9.8K ﹤0.01% 4902
2021
Q3 		$40K Sell
2,629
-371
-12% -$6.45K ﹤0.01% 4870
2021
Q2 		$56K Buy
3,000
+2,039
+212% +$37.6K ﹤0.01% 4766
2021
Q1 		$17K Sell
961
-445
-32% -$7.54K ﹤0.01% 5352
2020
Q4 		$22K Buy
1,406
+1,114
+382% +$13K ﹤0.01% 6595
2020
Q3 		$3K Sell
292
-4,647
-94% -$54.7K ﹤0.01% 7243
2020
Q2 		$62K Buy
+4,939
New +$62.9K ﹤0.01% 5896
2020
Q1 		– Sell
-1,352
Closed -$18K – 7794
2019
Q4 		$18K Buy
1,352
+674
+99% +$7.09K ﹤0.01% 6985
2019
Q3 		$6K Sell
678
-321
-32% -$3.04K ﹤0.01% 7294
2019
Q2 		$10K Buy
999
+246
+33% +$2.35K ﹤0.01% 7315
2019
Q1 		$8K Buy
753
+153
+26% +$1.3K ﹤0.01% 7319
2018
Q4 		$4K Hold
600
– – ﹤0.01% 7412
2018
Q3 		$8K Sell
600
-100
-14% -$1.16K ﹤0.01% 7417
2018
Q2 		$6K Hold
700
– – ﹤0.01% 7316
2018
Q1 		$3K Hold
700
– – ﹤0.01% 7317
2017
Q4 		$2K Hold
700
– – ﹤0.01% 7405
2017
Q3 		$2K Hold
700
– – ﹤0.01% 7055
2017
Q2 		$2K Hold
700
– – ﹤0.01% 7038
2017
Q1 		$3K Hold
700
– – ﹤0.01% 6950
2016
Q4 		$5K Hold
700
– – ﹤0.01% 6937
2016
Q3 		$6K Hold
700
– – ﹤0.01% 6734
2016
Q2 		$4K Hold
700
– – ﹤0.01% 6831
2016
Q1 		$5K Hold
700
– – ﹤0.01% 7015
2015
Q4 		$6K Hold
700
– – ﹤0.01% 6989
2015
Q3 		$6K Buy
700
+649
+1,273% +$6.45K ﹤0.01% 6665
2015
Q2 		$1K Buy
+51
New +$705 ﹤0.01% 7347

Other funds holding XENE

Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
NFT
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Citigroup's XENE Position: Q2 2026 in Review

Citigroup increased its Xenon Pharmaceuticals (XENE) stake by 658% in Q2 2026, buying an estimated $4.44M and bringing the position to 92,124 shares worth $5.56M. The position accounts for ﹤0.01% of the portfolio, ranked #2064.

Citigroup first reported a position in XENE in Q2 2015 and has held it in 44 quarters since. 58 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Citigroup held 92,124 shares of Xenon Pharmaceuticals worth $5.56M as of Q2 2026.
  • Citigroup bought 79,973 Xenon Pharmaceuticals shares in Q2 2026, an estimated $4.44M.
  • Xenon Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #2064 holding.
  • Citigroup first reported a position in Xenon Pharmaceuticals in Q2 2015 and has held it in 44 quarters since.
  • 58 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.